Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5222854 | 0.88 | KMT2A (0.52) | RAB9AKMT2AALDH1A1LMNAMEN1 | |
| SCHEMBL14520430 | 0.81 | SMN1; SMN2 (0.50) | NPC1RAB9AKMT2AALDH1A1LMNA | |
| SCHEMBL5219395 | 0.81 | NPC1 (0.51) | NPC1RAB9AKMT2AALDH1A1LMNA | |
| SCHEMBL5230740 | 0.77 | HDAC6 (0.72) | NPC1RAB9AKMT2AALDH1A1LMNA | |
| SCHEMBL23099741 | 0.73 | NPC1 (0.74) | NPC1RAB9AKMT2AALDH1A1LMNA | |
| SCHEMBL12375175 | 0.72 | HPGD (0.65) | KMT2ALMNAMEN1MAPK1HPGD | |
| SCHEMBL8760 | 0.72 | KMT2A (0.67) | KMT2AALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL13257633 | 0.71 | KMT2A (0.86) | NPC1KMT2AALDH1A1LMNAMEN1 | |
| SCHEMBL1155517 | 0.71 | ALDH1A1 (0.72) | NPC1RAB9AKMT2AALDH1A1LMNA | |
| SCHEMBL2245328 | 0.71 | MMP12 (0.70) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007049121-A1 | CRYSTAL FORM OF SODIUM; (3R,5R)-7-[4-BENZYLCARBAMOYL-2-(4-FLUOROPHENYL)-5-ISOPROPYL-IMIDAZOL-1-YL]-3,5-DIHYDROXY-HEPTANOATE | PFIZER PRODUCTS INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| EP-1740549-A2 | NOVEL IMIDAZOLES | Warner-Lambert Company LLC (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20060287378-A1 | Novel pyrroles and imidazoles | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| WO-2005105079-A2 | NOVEL IMIDAZOLES | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050239857-A1 | Novel imidazoles | BOLTON GARY L | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287378-A1 | Novel pyrroles and imidazoles | PPIP5K2, PPIE, PPOX | NPC1 3514/4885RAB9A 2152/4885KMT2A 3468/4885 |
| US-20050239857-A1 | Novel imidazoles | HMGCR, HMGB2, HMGB3 | NPC1 120/4885RAB9A 3634/4885KMT2A 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.